Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of Indoleamine 2-3 Dioxygenase (IDO) and EGFR Co-expression in Breast Cancer Tissue by Immunohistochemistry

  • Bi, Wei-Wei (Department of Biological Engineering College of Pharmacy Jilin University) ;
  • Zhang, Wei-Hua (Siping Hospital of China Medical University) ;
  • Yin, Gui-Hua (Siping Hospital of China Medical University) ;
  • Luo, Hong (Siping Hospital of China Medical University) ;
  • Wang, Shou-Qin (Siping Hospital of China Medical University) ;
  • Wang, Hongran (Department of Molecular and Cellular Biology, Baylor College of Medicine) ;
  • Li, Chao (TuoHua Biological Technology Company) ;
  • Yan, Wei-Qun (Department of Biological Engineering College of Pharmacy Jilin University) ;
  • Nie, De-Zhi (TuoHua Biological Technology Company)
  • Published : 2014.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: To determine the amount of co-expression of IDO and EGFR in breast cancer patients. Materials and Methods:In order to obtain the distribution of co-expression of IDO and EGFR in breast cancer, we tested 110 breast cancer paraffin tissue blocks with immunohistochemical methods. Then we investigated the relationship between the diagnostic and pathologic characteristics (tumor size, lymph node status, histologic grade, the gene expression of ER, PR, HER2, p53, Ki67 and PCNA) with the situation of co-expression of IDO and EGFR by reviewing the medical records of 32 breast cancer patients. Results: Among 110 breast cancers, 32 cases demonstrated IDO and EGFR co-expression (29.1%), IDO and EGFR synchronous co-expression being found in 19.1% and asynchronous in 10.0%. Conclusions: IDO and EGFR were co-expressed in breast cancer, including synchronous and asynchronous co-expression. The results suggest that considering IDO and EGFR as two indicators for breast cancer treatment or prognosis analysis provides a potential option of individual treatment for the portion of breast cancer patients with co-expression of IDO and EGFR.

Keywords

References

  1. Arteaga C (2003). Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol, 30, 3-14. https://doi.org/10.1053/S0093-7754(03)00551-7
  2. Abediankenari S, Jeivad F (2013). Epidermal growth factor receptor gene polymorphisms and gastric cancer in Iran. Asian Pac J Cancer Prev, 14, 3187-90. https://doi.org/10.7314/APJCP.2013.14.5.3187
  3. Brandacher G , Perathoner A, Ladurner R, et al (2006). Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res, 12, 1144-51. https://doi.org/10.1158/1078-0432.CCR-05-1966
  4. Cheang MC, Voduc D, Bajdik C, et al (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 14, 1368-76. https://doi.org/10.1158/1078-0432.CCR-07-1658
  5. Hu Q, Luo Z , Xu T, et al (2014). FOXA1: a promising prognostic marker in breast cancer. Asian Pac J Cancer Prev, 15, 11-6. https://doi.org/10.7314/APJCP.2014.15.1.11
  6. Ino K, Yoshida N, Kajiyama H, et al (2006). Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer, 95, 1555-61. https://doi.org/10.1038/sj.bjc.6603477
  7. Kim H, Choi DH, Park W, et al (2013). Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. Radiat Oncol J, 31, 222-7. https://doi.org/10.3857/roj.2013.31.4.222
  8. Mansfield AS, Heikkila PS, Vaara AT, et al (2009). Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer, 15, 231.
  9. Okamoto H, Fujishima F, Nakamura Y, et al (2013). Significance of CD133 expression in esophageal squamous cell carcinoma. World J Surg Oncol, 11, 51. https://doi.org/10.1186/1477-7819-11-51
  10. Rakha EA, Elsheikh SE, Aleskandarany MA, et al (2009). Triplenegative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res, 15, 2302-10. https://doi.org/10.1158/1078-0432.CCR-08-2132
  11. Tan DS, Marchio C, Jones RL, et al (2008). Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Tr, 111, 27-44. https://doi.org/10.1007/s10549-007-9756-8
  12. Tong L, Yang XX, Liu MF, et al (2012). Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. Asian Pac J Cancer Prev, 13, 5599-603. https://doi.org/10.7314/APJCP.2012.13.11.5599
  13. Van der Loos CM, Das PK, Houthoff HJ (1987). An immunoenzyme triple-staining method using both polyclonal and monoclonal antibodies from the samespecies. Application of combined direct, indirect, and avidin-biotin complex (ABC) technique. J Histochem Cytochem, 35, 1199-204. https://doi.org/10.1177/35.11.2443555
  14. Van Noorden S, Stuart MC, Cheung A, et al (1986). Localization of human pituitary hormones by multiple immunoenzyme staining procedures using monoclonal andpolyclonal antibodies. J Histochem Cytochem, 34, 287-92. https://doi.org/10.1177/34.3.2419389

Cited by

  1. Gene silencing of indoleamine 2,3-dioxygenase hinders tumor growth through angiogenesis inhibition vol.50, pp.6, 2017, https://doi.org/10.3892/ijo.2017.3975
  2. ) gene expression by real-time PCR among patients with lung cancer pp.00219541, 2019, https://doi.org/10.1002/jcp.28057